SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

RYBREVANT FASPRO

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA); earlier-stage label-expansion work ongoing
Time to market
Already approved and on the U.S. market: the subcutaneous RYBREVANT FASPRO form cleared FDA as a Type 5 new-formulation approval (Dec 17 2025, BLA 761433; Feb 13 2026, BLA 761484) and in first-line NSCLC with LAZCLUZE (Jan 21 2026). The IV form, RYBREVANT, has been marketed since May 2021.
Why 3/10
No hard, dated binary catalyst in the next ~12 months: RYBREVANT FASPRO is already FDA-approved and commercializing (approvals Dec 17 2025, Jan 21 2026, Feb 13 2026), and the Apr 14 2026 head-and-neck Breakthrough Therapy Designation is a status, not a dated PDUFA/pivotal readout, so the score caps at the approved-with-no-pending-decision band (3), further tempered because JNJ is a ~$600B mega-cap where past FASPRO approvals moved the stock between roughly -0.5% and +1.5% in 5 days.
Actionable Insight NEUTRAL

There is no near-term FDA binary to trade here, the defining approvals already happened (Dec 2025–Feb 2026) and moved JNJ shares by well under 2%. Watch instead for (1) JNJ quarterly earnings commentary on RYBREVANT-franchise sales, and (2) any registration path triggered by the April 2026 head-and-neck Breakthrough Therapy Designation, plus results posting for the small Phase 2 amivantamab+docetaxel NSCLC study (completed May 2026).

Price Chart

Loading chart...

Executive Summary

RYBREVANT FASPRO is the subcutaneous form of Johnson & Johnson's (JNJ, via Janssen) lung-cancer antibody amivantamab, co-formulated with hyaluronidase. SecBot's ingested FDA/SEC records show it was approved by the FDA in Dec 2025–Feb 2026 (Type 5 new-formulation BLAs 761433/761484 and a Jan 21 2026 NSCLC approval paired with LAZCLUZE), and it received a Breakthrough Therapy Designation for advanced head and neck cancer on Apr 14 2026. It is a genuine commercial asset inside JNJ's Innovative Medicine oncology franchise, but it is one drug in a ~$600B market-cap company: historical approval-day price moves on JNJ were roughly -0.5% to +1.5% in the five days after each event, and no dated regulatory binary is scheduled in the next 12 months, so the net investor read is neutral for the stock.

How It Works

Amivantamab is a bispecific antibody, one engineered protein that latches onto two growth-signal receptors (EGFR and MET) found on certain lung-cancer cells, flagging them for immune attack. It has long been given as a slow intravenous (IV) infusion. The "FASPRO" version adds recombinant human hyaluronidase, an enzyme that temporarily loosens the gel-like tissue under the skin so the same drug can be injected subcutaneously in minutes, which J&J describes as enabling the simplest, shortest administration time for a first-line combination regimen (given with the pill lazertinib, brand LAZCLUZE, in EGFR-mutant non-small cell lung cancer).

Trial Status

Marketed drug. Per ingested FDA/SEC records: Type 5 new-formulation approvals Dec 17 2025 and Feb 13 2026; NSCLC approval Jan 21 2026; Breakthrough Therapy Designation for advanced head and neck cancer Apr 14 2026. In trials: Phase 2 amivantamab+docetaxel in metastatic NSCLC (NCT06532032, 12 patients) completed May 14 2026 with results not yet posted, and Phase 2 amivantamab+capmatinib in unresectable metastatic NSCLC (NCT05488314, 57 patients) active/not recruiting with estimated primary completion June 9 2026.

The Two-Sided Case

▲ Bull Case4
Already FDA-approved and commercializing, no approval risk left: RYBREVANT FASPRO cleared FDA on Dec 17 2025 (BLA 761433) and Feb 13 2026 (BLA 761484) as a Type 5 new-formulation, plus a Jan 21 2026 NSCLC approval in first-line combination with LAZCLUZE.
Convenience is a real differentiator: the Jan 21 2026 approval detail notes the subcutaneous form 'enables the simplest, shortest administration time for a first-line combination regimen', a meaningful clinical-practice upgrade over hour-long IV infusions of the original RYBREVANT (approved May 21 2021).
Expansion optionality: the U.S. FDA granted RYBREVANT FASPRO Breakthrough Therapy Designation for advanced head and neck cancer on Apr 14 2026 (per SEC-extracted catalyst on JNJ's 8-K filing), opening a second, larger indication runway beyond NSCLC.
Supportive sell-side backdrop: 22 JNJ analysts tracked show a Buy-leaning consensus (15 Buy + 7 Strong Buy, 9 Hold, 0 Sell) with a mean target of $272.50 vs. a $262.37 price (+6.7% implied upside), and multiple firms raised price targets in July–Aug 2026 (TD Cowen $300, Citigroup $298, Morgan Stanley $294).
▼ Bear Case5
Negligible single-drug price impact: JNJ is a mega-cap (market snapshot ~$617.8B at the time of the Aug 2026 8-K report), and RYBREVANT FASPRO approvals moved the stock only roughly -0.5% to +1.5% in the 5 days after each FDA event, the catalyst is already priced in.
No hard, dated catalyst in the next 12 months: the head-and-neck Breakthrough Therapy Designation (Apr 14 2026) is a status with no PDUFA date or pivotal readout in the data; the two tracked Phase 2 combo studies are small (12 and 57 patients) and one completed in May 2026 with results still not posted.
Formulation switch, not a new mechanism: FASPRO is the same amivantamab antibody given subcutaneously rather than a novel biology, so incremental sales are largely a convenience/market-share play inside a crowded EGFR-mutant NSCLC landscape (which also faces competition in the space).
Small-sample trial risk: the amivantamab+docetaxel Phase 2 (NCT06532032, 12 patients) is too small to be a pivotal readout, and disappointing combo data would not move JNJ anyway given portfolio breadth.
Insider activity is mildly bearish color: CEO Joaquin Duato exercised options and sold ~123k shares for roughly $32M on Aug 13 2026 (Form 4), though this is routine executive diversification at a dividend-paying mega-cap.

Upcoming Catalysts

  • Head-and-neck cancer development updates following the Apr 14 2026 Breakthrough Therapy Designation (potential registration filing, no date yet in the data)
  • Posting of results from the completed Phase 2 amivantamab+docetaxel metastatic-NSCLC study (NCT06532032, completed May 14 2026)
  • Phase 2 amivantamab+capmatinib NSCLC data (NCT05488314, estimated primary completion June 9 2026)
  • Quarterly JNJ earnings commentary on RYBREVANT-franchise sales (Innovative Medicine segment)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov